Retina and Ocular Diabetes
Diabetic retinopathy under treatment: Why you shouldn’t miss follow-up appointments
Read this guide
High Vision
Schedule an appointment
Choose how to contact the office.
Retina and Ocular Diabetes
Choose how to contact the office.
In brief: Diabetic retinopathy requires regular checkups even when your vision seems stable, because damage can progress silently between appointments. Keeping up with the follow-up schedule recommended by your specialist is the most effective way to protect your vision in the long term. If you face barriers to attending, let your health care team know: there are always options.
Being diagnosed with diabetic retinopathy and starting treatment can bring up conflicting feelings: you feel fine, your vision hasn’t changed, and yet you have to keep coming back to the office again and again. It’s understandable to wonder whether keeping up that pace of checkups is really worthwhile as part of the follow-up and treatment of diabetic retinopathy. The short answer is yes, and here’s why.
Diabetic retinopathy progresses silently because the damage occurs in microscopic blood vessels in the retina, an area of the eye that has no pain nerve endings. It is a progressive microvascular complication of diabetes that damages the retinal vasculature through chronic hyperglycemia, leading to increased vascular permeability, capillary occlusion, and, ultimately, neovascularization. (Global Prevalence of Diabetic Retinopathy Over the Last Decade (2015–2025): A Scoping Review)
This process can last for months or years before you notice any changes in your vision. The disease occurs in several stages, from mild nonproliferative diabetic retinopathy to advanced stages such as proliferative retinopathy and diabetic macular edema, the latter being an important cause of central vision loss. (Global Prevalence of Diabetic Retinopathy Over the Last Decade (2015–2025): A Scoping Review)
Because the damage is gradual and invisible, skipping checkups gives it time to progress without supervision. Not feeling anything doesn’t mean everything is fine; it only means the damage has not yet crossed the threshold at which you can notice it.
New abnormal blood vessels may develop, fluid may build up in the macula, or the response to treatment may change between scheduled appointments—all without obvious symptoms. Understanding the differences between stages helps explain why follow-up frequency varies.
Stage: Mild NPDR
What happens in the retina: Microaneurysms, small hemorrhages
Common symptoms: Generally none
Follow-up urgency: Annual checkup or as recommended
Stage: Moderate NPDR
What happens in the retina: More hemorrhages, exudates
Common symptoms: Vision may be slightly blurry
Follow-up urgency: Every 6 to 9 months
Stage: Severe NPDR
What happens in the retina: Extensive vascular occlusions, ischemia
Common symptoms: There may be no change in vision
Follow-up urgency: Every 3 to 6 months
Stage: Proliferative retinopathy (PDR)
What happens in the retina: Fragile new blood vessels; risk of vitreous hemorrhage
Common symptoms: Floaters, dimmed vision
Follow-up urgency: Close follow-up; possible immediate treatment
Stage: Diabetic macular edema (DME)
What happens in the retina: Fluid in the macula that affects central vision
Common symptoms: Distorted or blurry images in the center of your vision
Follow-up urgency: Frequent follow-up during active treatment
If you suddenly notice new floaters, a sudden dimming of your vision, or sudden vision loss, go to an ophthalmic emergency department that same day. These symptoms can’t wait for a scheduled appointment.
How often you need checkups depends on the stage of your retinopathy and whether you are receiving active treatment. There is no one-size-fits-all answer: your specialist will determine the interval based on how your retina responds. The American Academy of Ophthalmology (AAO) recommends follow-up every one to two years for people with diabetes who have no retinopathy, annually for mild NPDR, every six to nine months for moderate NPDR, and every three to six months for severe NPDR. (Prevalence and Progression of Diabetic Retinopathy in a Tertiary Care Setting: An Initial Review With Recommended Screening Protocols)
Once treatment with intravitreal injections begins, patients receiving anti-VEGF agents may be reexamined as soon as one month after the injection. The AAO also emphasizes that effective treatment depends on timely intervention, even when vision seems good, and that current treatments often require multiple visits over time. (© 2024 American Academy of Ophthalmology Introduction)
If it is difficult for you to attend appointments because of transportation, work, or cost, talk with your care team. Postponing an appointment without notifying your team is different from communicating a real barrier; in the latter case, alternatives can always be explored.
At each follow-up visit, specific tests are used to see what the eye does not reveal at a glance. Knowing about them can reduce anxiety about the procedure and help you understand what the specialist is evaluating.
Clinical follow-up also includes an evaluation of systemic health: blood pressure, serum lipids, kidney function, and glycated hemoglobin (HbA1c). (Diabetic Retinopathy Preferred Practice Pattern®) These data are as important as eye images because metabolic control directly influences the progression of retinopathy.
Several established approaches are available to treat diabetic retinopathy. The choice depends on the stage, whether macular edema is present, and each patient's individual response. No treatment guarantees a specific outcome, but all are supported by evidence.
Intravitreal injections of anti-VEGF agents. Anti-VEGF agents are effective in treating diabetic macular edema with vision loss. They also reduce the severity of diabetic retinopathy and effectively treat proliferative retinopathy. (AAO Diabetic Retinopathy Guideline Summary - Guideline Central) As Dr. Jaclyn Kovach noted during the AAO annual meeting 2024: “Anti-VEGF therapy is the standard of care and has an additional benefit: it can improve the severity of DR in patients with and without macular edema.” (PPP Guidelines for Diabetic Retinopathy at AAO 2024 - Media MICE)
Panretinal photocoagulation (PRP). Panretinal photocoagulation remains an important treatment for proliferative diabetic retinopathy. (AAO Diabetic Retinopathy Guideline Summary - Guideline Central) It is used in advanced stages to reduce the burden of abnormal blood vessels.
Vitrectomy. When there is tractional retinal detachment or vitreous hemorrhage that does not resolve, vitrectomy is the indicated surgical approach. (PPP Guidelines for Diabetic Retinopathy at AAO 2024 - Media MICE)
Observation with close follow-up. In eyes with good visual acuity and center-involving macular edema, treatment may reasonably be deferred until visual acuity is affected (20/30 or worse). (AAO Diabetic Retinopathy Guideline Summary - Guideline Central)
Retinal care doesn’t happen only in the office: what happens between checkups matters, too. Systemic factors are the most powerful allies of ophthalmic treatment.
Sustained blood sugar control. The 2024 review of the AAO guidelines includes an important warning: rapidly adjusting blood sugar control with newer agents may precipitate an initial worsening of retinopathy. (Diabetic retinopathy guidelines — AAO 2024 vs ICO 2017 · Guideline Atlas) That’s why any change in diabetes treatment should be coordinated with your internist or endocrinologist and communicated to your ophthalmologist.
Blood pressure and lipid control. High blood pressure and dyslipidemia accelerate retinal blood vessel damage. Keeping them within the ranges recommended by your doctor helps stabilize retinopathy.
Keeping track of new symptoms. Keep a note of any vision changes you notice between appointments: distortion of straight lines, new dark spots, or sudden vision loss. Share this information at your next appointment, or seek care right away if the change is sudden.
Attending all scheduled appointments. Only 60% of people with diabetes receive the recommended annual screening exams for retinopathy. (Diabetic Retinopathy Preferred Practice Pattern® - Ophthalmology) Every missed checkup means the clinical team lacks information needed to make timely decisions.
If you have questions about your follow-up or have missed an appointment, the most helpful step is to get back in touch with your specialist promptly. You don’t need to wait until your next scheduled appointment to ask.
At High Vision, the retina team can guide you on the follow-up plan that’s right for your case and help answer questions between checkups. Schedule an assessment to review your current situation.
No. Diabetic retinopathy progresses without visual symptoms in its early and moderate stages. Keeping up with follow-up is the only way to detect changes before they permanently affect your vision. Your specialist determines how often you need checkups based on the condition of your retina.
The duration varies by patient and by how the retina responds to treatment. Some cases require periodic injections for months or years. Your ophthalmologist will adjust the frequency based on follow-up tests, with no fixed, predetermined timeframe.
Contact your clinic as soon as possible to reschedule. Don’t cancel without letting them know: the team can help you find an alternative and assess whether waiting poses any risk in your particular case.
Yes. Diabetic retinopathy is a systemic complication, so it can affect both eyes, though not necessarily at the same stage. That’s why every appointment includes an examination of both eyes.
Better blood sugar control may slow progression and improve the response to treatment, but it does not reverse existing damage. In addition, a very rapid adjustment in blood sugar can temporarily worsen retinopathy, so it should be done under coordinated medical supervision.
Yes. People with diabetes are at higher risk of developing cataracts and glaucoma. The AAO recommends referring patients for ophthalmologic follow-up to detect potentially reversible causes of vision loss, such as cataracts, glaucoma, or refractive changes. (AAO Diabetic Retinopathy Guideline Summary - Guideline Central) A comprehensive exam evaluates all of these conditions.